Camurus (CAMX) investor relations material

Financial performance and outlook

• Q2 2026 operating margin was 42%; cash position was SEK 4.1bn. Sustainable profitability since 2022.

• FY2026 revenue outlook: SEK 2.6–2.9bn, midpoint +21% vs. 2025; operating result outlook: SEK 0.9–1.2bn, midpoint +20% vs. 2025. Excludes potential licensing revenues.

Commercial portfolio

• Buvidal had 77,000 patients in treatment at end-June 2026; Q2 market growth was 19% YoY and share exceeded 80% of Australia’s LAIB segment. Target: 100,000 patients by end-2027.

• Brixadi Q2 2026 net revenue grew 42% YoY and 20% QoQ; share exceeded 30% of the US LAIB segment.

• Oczyesa, a long-acting octreotide depot for acromegaly, received EU and UK approvals in 2025; launched in Germany and available in Sweden.

Pipeline and partnerships

• CAM2029 ACROINNOVA 1: 77.2% vs. 37.5% achieved IGF-1 ≤1 ULN with CAM2029 vs. placebo (p=0.00018); reported improvements in treatment convenience, quality of life and satisfaction.

• CAM2029 SORENTO Phase 3 enrolled 332 patients with GEP-NET; primary endpoint is PFS superiority vs. standard of care (HR 0.65), with top-line results expected after 194 PFS events, targeted for Q4 2026.

• CAM2029 POSITANO Phase 2 met its primary endpoint in PLD: 4.3% reduction in height-adjusted total liver volume vs. placebo at week 52 (p=0.044).

• CAM2056 Phase 1b Day 85 weight change was -9.3% at 10 mg vs. -5.2% with weekly semaglutide; Phase 2b study planned to start H2 2026.

• Lilly collaboration covers long-acting incretins, with up to $290m in license, development and regulatory milestones, up to $580m in sales milestones, and tiered mid-single-digit royalties.